Novavax's earnings are likely due within the next couple of weeks. The vaccine developer was part of Operation Warp Speed, receiving $1.8bn of funding from the US government to develop a COVID vaccine ...

Novavax’s alliance with Sanofi came at an opportune time for the beleaguered vaccine developer. Its protein-based Covid-19 vaccine never reached the revenue highs achieved by the messenger RNA ...

Five years ago, Novavax (NASDAQ: NVAX) was a little-known clinical-stage biotech whose leading pipeline candidate was an influenza vaccine. Then came the pandemic. The company quickly grew in ...

On Thursday, Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the consensus of $84.35 million. The decrease was due to lower ...

Novavax's Q1 2024 earnings were so-so, but a major partnership with Sanofi sent its share price soaring by 200%. The Sanofi deal provides essential funding but restricts Novavax's future earning ...

(Reuters) - Novavax Inc has begun a large late-stage study of its experimental COVID-19 vaccine in the United States, the drug developer said on Monday, after delaying the trial twice due to issues in ...

On that day, Novavax is projected to report earnings of -$0.67 per share, which would represent year-over-year growth of 53.47%. In the meantime, our current consensus estimate forecasts the revenue ...

Novavax's protein-based shot is an option for COVID vaccination this season, joining refreshed formulas from Moderna and Pfizer. Jessica was a writer on the Wellness team, with a focus on health ...